マラリアワクチン市場：タイプ、薬剤、エンドユーザー別-2025-2030年の世界予測

マラリアワクチン市場の2023年の市場規模は6,434万米ドルで、2024年には8,088万米ドルに達すると予測され、CAGR 25.78%で成長し、2030年には3億2,066万米ドルに達すると予測されています。

マラリアワクチン市場は、特にアフリカ、東南アジア、ラテンアメリカの一部を中心とするマラリア流行地域で、マラリア対策に重要な役割を果たすことで定義されています。マラリアワクチンの必要性は、マラリアが重大な罹患率と死亡率をもたらし、世界の健康被害を持続的にもたらしていることによって強調されています。マラリアワクチンの主な用途は、感染率とトランスミッションを減少させるための予防接種であり、感染地域における公衆衛生の向上と経済生産性の向上に貢献します。主なエンドユーザーには、政府保健機関、非政府組織、公衆衛生イニシアティブ、流通規模としては民間ヘルスケアプロバイダーが含まれます。市場の洞察によると、研究開発投資の増加、バイオテクノロジーの進歩、世界ヘルスパートナーシップなどの要因が市場成長にプラスの影響を与えています。最近の動向としては、WHOによるRTS,S/AS01（モスキリックス）ワクチンの承認があり、大規模な予防接種プログラムへの拡大の大きなチャンスとなっています。こうした機会を効果的に活用するためには、国際保健機関との戦略的パートナーシップの活用やコールドチェーン・インフラへの投資が推奨されます。

限界と課題には、ワクチン配布における物流のハードル、遠隔地における認識不足、副作用の可能性、特に資源が限られた環境におけるワクチン保管の問題などがあります。さらに、資金調達の不確実性や、ワクチンに部分的な耐性を持つマラリア株の出現が、さらなる成長の障壁となっています。しかし、技術革新のチャンスは豊富にあり、特に、より広い菌株をカバーし、有効性を向上させたワクチンを開発することが重要です。費用対効果の高い製造方法と、より容易な送達を可能にするマルチプラットフォーム技術の調査は、事業成長の原動力となります。厳しい規制枠組の影で発展する市場は、持続可能性とアクセシビリティの必要性によって大きく動かされ、非常にダイナミックであり続けています。したがって、企業は手頃な価格を保証する協力モデルに焦点を当て、低所得地域における物流・流通効率を高めるテクノロジー主導のソリューションを優先しなければならないです。

市場力学：急速に進化するマラリアワクチン市場の主要市場インサイトの解明

マラリアワクチン市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響についてより明確に理解することができます。

• 市場促進要因
  • 定期予防接種プログラムの急増
  • マラリアワクチンの入手可能性、入手しやすさ、政府による好意的な支援の増加
  • マラリアに対する患者の意識の高まりと発生率
• 市場抑制要因
  • ワクチンの高コスト
• 市場機会
  • 新規アジュバントと画期的なワクチン送達プログラムの継続的登場
  • ワクチンに関する製薬業界の進歩の高まり
• 市場の課題
  • 厳しい規制シナリオ

ポーターの5つの力：マラリアワクチン市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：マラリアワクチン市場における外部からの影響の把握

外部マクロ環境要因は、マラリアワクチン市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析マラリアワクチン市場における競合情勢の把握

マラリアワクチン市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスマラリアワクチン市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、マラリアワクチン市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨マラリアワクチン市場における成功への道筋を描く

マラリアワクチン市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 定期予防接種プログラムの増加
    • マラリアワクチンの可用性、アクセス性、政府による好意的なサポートの向上
    • マラリアに対する患者の意識と発症率の高まり
  • 抑制要因
    • ワクチンの高コスト
  • 機会
    • 新たなアジュバントと画期的なワクチン投与プログラムの継続的な出現
    • ワクチンに関する製薬業界の進歩
  • 課題
    • 厳格な規制シナリオ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 マラリアワクチン市場：タイプ別

• 赤血球ワクチン
• 多抗原ワクチン
• 赤血球前ワクチン

第7章 マラリアワクチン市場エージェント別

• ハマダラカ属
• 熱帯熱マラリア原虫
• 三日熱マラリア原虫

第8章 マラリアワクチン市場：エンドユーザー別

• クリニック
• コミュニティセンター
• 病院

第9章 南北アメリカのマラリアワクチン市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のマラリアワクチン市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのマラリアワクチン市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Amyris, Inc.
• Bharat Biotech International Limited
• Cadila Healthcare Ltd.
• CellFree Sciences Co.,Ltd.
• GenVec, Inc.
• GlaxoSmithKline PLC
• Ipca Laboratories Limited
• Merck & Co., Inc
• Mymetics Corporation
• Novartis AG
• Novavax, Inc.
• Precigen, Inc.
• Sanaria Inc.
• Sumaya Biotech
• Sun Pharmaceutical Industries Limited

LIST OF FIGURES

• FIGURE 1. MALARIA VACCINE MARKET RESEARCH PROCESS
• FIGURE 2. MALARIA VACCINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL MALARIA VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES MALARIA VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES MALARIA VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. MALARIA VACCINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL MALARIA VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL MALARIA VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. MALARIA VACCINE MARKET DYNAMICS
• TABLE 7. GLOBAL MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL MALARIA VACCINE MARKET SIZE, BY ERYTHROCYTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL MALARIA VACCINE MARKET SIZE, BY MULTI-ANTIGEN VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL MALARIA VACCINE MARKET SIZE, BY PRE-ERYTHROCYTIC VACCINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL MALARIA VACCINE MARKET SIZE, BY ANOPHELES SPECIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL MALARIA VACCINE MARKET SIZE, BY PLASMODIUM FALCIPARUM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL MALARIA VACCINE MARKET SIZE, BY PLASMODIUM VIVAX, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL MALARIA VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL MALARIA VACCINE MARKET SIZE, BY COMMUNITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL MALARIA VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. CANADA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 31. CANADA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES MALARIA VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. CHINA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 48. CHINA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 49. INDIA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 51. INDIA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA MALARIA VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. ITALY MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 103. ITALY MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. POLAND MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 115. POLAND MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. QATAR MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 118. QATAR MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY AGENT, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM MALARIA VACCINE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 146. MALARIA VACCINE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. MALARIA VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

The Malaria Vaccine Market was valued at USD 64.34 million in 2023, expected to reach USD 80.88 million in 2024, and is projected to grow at a CAGR of 25.78%, to USD 320.66 million by 2030.

The malaria vaccine market is defined by its critical role in combating the malaria epidemic, particularly in malaria-endemic regions predominantly across Africa, Southeast Asia, and parts of Latin America. The necessity of a malaria vaccine is underscored by the persistent global health burden malaria poses, leading to significant morbidity and mortality. The primary application of malaria vaccines involves preventive inoculations to reduce infection rates and transmission, thus contributing to public health improvement and economic productivity in affected regions. Key end-users include government health bodies, non-governmental organizations, public health initiatives, and potentially private healthcare providers as distribution scales. Market insights indicate that factors such as increasing R&D investments, advancements in biotechnology, and global health partnerships are positively influencing market growth. Recent developments include WHO's approval of the RTS,S/AS01 (Mosquirix) vaccine, which presents significant opportunity for expansion into larger immunization programs. Leveraging strategic partnerships with international health agencies and investing in cold chain infrastructure are recommended to harness these opportunities effectively.

Limitations and challenges include logistical hurdles in vaccine distribution, lack of awareness in remote areas, potential side effects, and vaccine storage issues, particularly in resource-limited settings. Moreover, funding uncertainties and the emergence of malaria strains with partial vaccine resistance pose additional growth barriers. However, opportunities for innovation abound, particularly in developing vaccines with broader strain coverage and improved efficacy. Research into cost-effective production methods and multi-platform technologies that facilitate easier delivery can drive business growth. The market, evolving under the shadow of stringent regulatory frameworks, remains highly dynamic and primarily driven by the need for sustainability and accessibility. Hence, companies must focus on collaborative models that ensure affordability and prioritize technology-driven solutions that enhance logistics and distribution efficiency in lower-income regions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Malaria Vaccine Market

The Malaria Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Proliferation in the number of routine immunizations programs
  • Rising availability, accessibility and favorable government support for malaria vaccine
  • Growing patient awareness and incidence of malaria
• Market Restraints
  • High cost of the vaccines
• Market Opportunities
  • Ongoing advent of novel adjuvants and breakthrough vaccine delivery programs
  • Rising advancements in pharmaceutical industry for vaccines
• Market Challenges
  • Rigid regulative scenarios

Porter's Five Forces: A Strategic Tool for Navigating the Malaria Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Malaria Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Malaria Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Malaria Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Malaria Vaccine Market

A detailed market share analysis in the Malaria Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Malaria Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Malaria Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Malaria Vaccine Market

A strategic analysis of the Malaria Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Malaria Vaccine Market, highlighting leading vendors and their innovative profiles. These include Amyris, Inc., Bharat Biotech International Limited, Cadila Healthcare Ltd., CellFree Sciences Co.,Ltd., GenVec, Inc., GlaxoSmithKline PLC, Ipca Laboratories Limited, Merck & Co., Inc, Mymetics Corporation, Novartis AG, Novavax, Inc., Precigen, Inc., Sanaria Inc., Sumaya Biotech, and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Malaria Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Erythrocytic Vaccine, Multi-Antigen Vaccine, and Pre-Erythrocytic Vaccine.
• Based on Agent, market is studied across Anopheles Species, Plasmodium Falciparum, and Plasmodium Vivax.
• Based on End-User, market is studied across Clinics, Community Centers, and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Proliferation in the number of routine immunizations programs
    • 5.1.1.2. Rising availability, accessibility and favorable government support for malaria vaccine
    • 5.1.1.3. Growing patient awareness and incidence of malaria
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of the vaccines
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing advent of novel adjuvants and breakthrough vaccine delivery programs
    • 5.1.3.2. Rising advancements in pharmaceutical industry for vaccines
  • 5.1.4. Challenges
    • 5.1.4.1. Rigid regulative scenarios
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Malaria Vaccine Market, by Type

• 6.1. Introduction
• 6.2. Erythrocytic Vaccine
• 6.3. Multi-Antigen Vaccine
• 6.4. Pre-Erythrocytic Vaccine

7. Malaria Vaccine Market, by Agent

• 7.1. Introduction
• 7.2. Anopheles Species
• 7.3. Plasmodium Falciparum
• 7.4. Plasmodium Vivax

8. Malaria Vaccine Market, by End-User

• 8.1. Introduction
• 8.2. Clinics
• 8.3. Community Centers
• 8.4. Hospitals

9. Americas Malaria Vaccine Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Malaria Vaccine Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Malaria Vaccine Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Amyris, Inc.
• 2. Bharat Biotech International Limited
• 3. Cadila Healthcare Ltd.
• 4. CellFree Sciences Co.,Ltd.
• 5. GenVec, Inc.
• 6. GlaxoSmithKline PLC
• 7. Ipca Laboratories Limited
• 8. Merck & Co., Inc
• 9. Mymetics Corporation
• 10. Novartis AG
• 11. Novavax, Inc.
• 12. Precigen, Inc.
• 13. Sanaria Inc.
• 14. Sumaya Biotech
• 15. Sun Pharmaceutical Industries Limited